Trending
Stocks.org
You are at:»»Most Volatile: Plug Power (NASDAQ:PLUG), AirMedia Group Inc. (ADR) (NASDAQ:AMCN), Diversified Restaurant (NASDAQ:BAGR), Fate Therapeutics (NASDAQ:FATE)

Most Volatile: Plug Power (NASDAQ:PLUG), AirMedia Group Inc. (ADR) (NASDAQ:AMCN), Diversified Restaurant (NASDAQ:BAGR), Fate Therapeutics (NASDAQ:FATE)

273
By on Economy

Plug Power Inc. (NASDAQ:PLUG) will be profitable by the end of the year and the company expects to announce two or three major deals in 2014. On last trading day Plug Power Inc. (NASDAQ:PLUG) ended up -16.12%lower to close at $6.71 while trading in the range of $6.58 – $7.99. Its return on assets (ROA) is -110.80% while return on investment (ROI) is -180.80%.Plug Power Inc. (NASDAQ:PLUG) monthly performance is 79.41%.

AirMedia Group Inc. (NASDAQ:AMCN), a leading operator of out-of-home advertising platforms in China targeting mid-to-high-end consumers, on 12 march announced that it will conduct overseas non-deal roadshows in New York, Boston, San Francisco and Hong Kong. AirMedia Group Inc. (ADR) (NASDAQ:AMCN) in last trading activity ended up at $2.00 with day range of $1.96 – $2.49. Company weekly performance is -24.24% while its quarterly performance stands at 16.28%.AirMedia Group Inc. (ADR) (NASDAQ:AMCN) is -38.27% away from its 52 week high.

Diversified Restaurant Holdings, Inc. (NASDAQ:BAGR) operator of Bagger Dave’s Burger Tavern and one of the largest franchisees of Buffalo Wild Wings, announced results for fiscal 2013 and the fourth quarter ended Dec. 29, 2013. Diversified Restaurant Holdings, Inc. (NASDAQ:BAGR) belongs to Services sector with market capitalization of 137.83 million and has 46.30% insider ownership. In last trading activity company’s stock closed at $5.29 while opening price was 4.30.

Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced the enrollment of the first patient in its “PUMA” (PROHEMA(R) in UMbilical cord blood transplant in Adults) study, a Phase 2 clinical trial of PROHEMA(R) (16, 16-dimethyl prostaglandin E2, or dmPGE2, modulated cord blood) using the Company’s nutrient-rich media formulation. On Friday shares of Fate Therapeutics Inc. (NASDAQ:FATE) opened at 8.85 and closed at $11.15. This year Company’s Earnings per Share (EPS) growth is -15.74 and next year’s estimated EPS growth is 28.30%. Analysts mean target price for Fate Therapeutics Inc. (NASDAQ:FATE) is 12.50.

Get Free Updates and Stock Alerts!



*We only send one email per week
Share.

Related Posts

Get Winning Stock Alerts!

Our track record speaks for itself! Our last 7 alerts have delivered combined gains in excess of 300% and there are no signs of slowing down. Join UltimateStockAlerts.com now before you miss out on our next big runner!

We will never sell or share your information.
Close